Contact
searchSearch
HMP Global

Biosimilars

Featured Article

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
Addressing and Understanding Challenges Linked With Adopting Biosimilars Into Practice
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
Identifying Pharmacist Knowledge of a Medication Drug Type
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
Most Pharmacists Show Good Grasp of Biosimilar Medications, Study Finds
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
Biosimilar Infliximab Appears Effective in Crohn`s Disease
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
Etanercept Biosimilar is Effective, Well-Tolerated for Rheumatoid Arthritis
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network

Newsfeed

News
Sermorelin Recalled Due to Lack of Process Control
10/22/2026
Rebecca Amrick
Sermorelin is under a voluntary Class II recall due to a lack of process control, affecting 7 vials.
Sermorelin is under a voluntary Class II recall due to a lack of process control, affecting 7 vials.
Sermorelin is under a voluntary...
10/22/2026
Pharmacy Learning Network
News
Tirzepatide/Niacinamide Recalled Due to Lack of Sterility Assurance
10/22/2026
Rebecca Amrick
A voluntary Class II recall has been issued for tirzepatide/niacinamide due to the product’s lack of sterility assurance, affecting 64 vials.
A voluntary Class II recall has been issued for tirzepatide/niacinamide due to the product’s lack of sterility assurance, affecting 64 vials.
A voluntary Class II recall has...
10/22/2026
Pharmacy Learning Network
News
Hydrocortisone Injection Recalled Due to the Failed Impurities Specifications
10/22/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for hydrocortisone sodium succinate injection due to failed impurities specifications, affecting 70 776 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for hydrocortisone sodium succinate injection due to failed impurities specifications, affecting 70 776 vials.
The US Food and Drug...
10/22/2026
Pharmacy Learning Network
PharmLaw
Illinois Lab Owner Accused of Falsifying COVID-19 Tests for Federal Reimbursement
10/21/2026
Grace Taylor, MS, MA
An Illinois laboratory owner faces federal wire fraud charges for allegedly submitting $66.2 million in fraudulent COVID-19 testing claims, including hundreds of thousands of tests that were never performed.
An Illinois laboratory owner faces federal wire fraud charges for allegedly submitting $66.2 million in fraudulent COVID-19 testing claims, including hundreds of thousands of tests that were never performed.
An Illinois laboratory owner...
10/21/2026
Pharmacy Learning Network
News
BioSpectra Tris/Tromethamine Recalled Due to Failed Stability Specifications
10/15/2026
Rebecca Amrick
BioSpectra voluntarily recalled 200 kg of tris/tromethamine after the product failed to meet stability specifications, prompting a Class II classification by the FDA.
BioSpectra voluntarily recalled 200 kg of tris/tromethamine after the product failed to meet stability specifications, prompting a Class II classification by the FDA.
BioSpectra voluntarily recalled...
10/15/2026
Pharmacy Learning Network
News
Fosfomycin Tromethamine Recalled Due to Failed Impurities Specifications
10/15/2026
Rebecca Amrick
A voluntary Class II recall has been issued for fosfomycin tromethamine granules for oral solution due to the product’s failure to meet impurities specifications.
A voluntary Class II recall has been issued for fosfomycin tromethamine granules for oral solution due to the product’s failure to meet impurities specifications.
A voluntary Class II recall has...
10/15/2026
Pharmacy Learning Network
News
IMAAVY Injection Recalled Due to the Presence of Particulate Matter
10/15/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for IMAAVY (nipocalimab-aahu) injection due to the presence of particulate matter, affecting 49 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for IMAAVY (nipocalimab-aahu) injection due to the presence of particulate matter, affecting 49 vials.
The US Food and Drug...
10/15/2026
Pharmacy Learning Network
PharmLaw
CVS $315 Million Settlement Highlights Controlled Substance Dispensing and Pharmacy Compliance Obligations
10/14/2026
Hannah Musick
CVS has agreed to pay $315 million to resolve federal allegations of unlawful controlled substance dispensing and improper Medicare billing, underscoring ongoing enforcement of pharmacy compliance requirements under the Controlled Substances...
CVS has agreed to pay $315 million to resolve federal allegations of unlawful controlled substance dispensing and improper Medicare billing, underscoring ongoing enforcement of pharmacy compliance requirements under the Controlled Substances...
CVS has agreed to pay $315...
10/14/2026
Pharmacy Learning Network
News
Estradiol Gel Recalled Due to Defective Container
10/08/2026
Rebecca Amrick
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a...
10/08/2026
Pharmacy Learning Network
News
Zoladex (Goserelin) Implant Recalled Due to Improper Temperature Regulation
10/08/2026
Rebecca Amrick
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has...
10/08/2026
Pharmacy Learning Network

Insights

Interactive Features

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use